Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308
NCT ID: NCT02001389
Last Updated: 2014-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
14 participants
INTERVENTIONAL
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT07169630
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
NCT07012993
A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
NCT01565343
Evaluation of PET Scan Timing Relative to AV-45 Injection Time
NCT01565356
A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain
NCT03089918
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EVP-6308; Arm 1
low dose, Capsule, Twice Daily, Day 1 through Day 3
EVP-6308
Arms 1, 2, 3, 4
EVP-6308; Arm 2
low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3
EVP-6308
Arms 1, 2, 3, 4
EVP-6308; Arm 3
high intermediate dose, Capsule, Once Daily, Day 1 through Day 3
EVP-6308
Arms 1, 2, 3, 4
EVP-6308; Arm 4
high dose, Capsule, Once Daily, Day 1 through Day 3
EVP-6308
Arms 1, 2, 3, 4
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EVP-6308
Arms 1, 2, 3, 4
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any disorder that may interfere with drug absorption.
* Clinically significant allergy or sensitivity to medications Positive test for human immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen, or Hepatitis C antibody.
* Pregnant or breast feeding.
* History of exposure to any radiation \>15 mSv/year (e.g., occupational or radiation therapy) over the past year.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
FORUM Pharmaceuticals Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EVP-6308-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.